Results 21 to 30 of about 16,704,778 (257)
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
Blood Cancer Journal, 2021 The recent decades have ushered in considerable advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve, AL amyloidosis-unrelated factors may impact mortality. In this study, we evaluated survival
Andrew Staron +6 more
semanticscholar +1 more source
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
Blood Cancer Journal, 2022 Dear editor, Systemic amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder caused by the extracellular deposition of misfolded immunoglobulin light chains as protein fibrils in tissues. This leads to vital organ damage. It is incurable and
J. Khwaja +20 more
semanticscholar +1 more source
PLoS ONE, 2022 BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy +11 more
doaj +1 more source
Systemic Immunoglobulin Light Chain Amyloidosis Presenting as Painful Penile Ulcers
Annals of Internal Medicine: Clinical Cases, 2022 Immunoglobulin light chain (AL) amyloidosis is a systemic form of amyloidosis that commonly affects the heart, kidney, liver, and nervous system. Penile involvement in AL amyloidosis is rare and thus often not considered in the differential diagnosis for
Crystal Lihong Yan +3 more
doaj +1 more source
Phase 1a/b Study of Monoclonal Antibody CAEL-101 (11-1F4) in Patients with AL Amyloidosis.
Blood, 2021 Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by pathologic deposition of immunoglobulin light chains as amyloid fibrils in vital organs, leading to organ impairment and eventual death. That the process is reversible was evidenced
C. Edwards +10 more
semanticscholar +1 more source
Comprehensive Review of AL amyloidosis: some practical recommendations
Blood Cancer Journal, 2021 Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC)
Rama Al Hamed +5 more
semanticscholar +1 more source
Amyloid: Journal of Protein Folding Disorders, 2021 AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was ...
V. Sanchorawala +8 more
semanticscholar +1 more source
Aggregation in AL Amyloidosis [PDF]
Biophysical Journal, 2014 Systemic light chain amyloidosis (AL amyloidosis) is a rare but fatal systemic amyloid disease. It usually strikes in the wake of myeloma, a form of cancer that affects plasma cells in the adaptive immune system. During plasma cell development from primary B cells, the immunoglobulin light chain (LC) genes undergo several rearrangements that leave each
Kathrin Andrich, Jan Bieschke
openaire +2 more sources
Supportive Care in AL Amyloidosis [PDF]
Acta Haematologica, 2020 Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response.
Joan Bladé +5 more
openaire +3 more sources
Strong positive light chain immunostaining in a patient with transthyretin amyloidosis
Hematology, 2023 The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen +5 more
doaj +1 more source